Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any gender
- People who are reasonably well and able to carry out daily activities (as assessed by their doctor using a standard scale called the ECOG scale, with a score of 0, 1, or 2)
- People who have been diagnosed with cancer that has spread to the brain, with at least one affected area in the brain larger than 2 cm that has not yet been treated
- People whose medical team has already planned a specific type of focused radiation treatment for their brain metastases
- Women who could become pregnant must have a negative blood pregnancy test within 14 days before joining the trial
- Women who could become pregnant must have been using a highly effective form of contraception for at least 4 weeks before the screening visit, and must agree to continue using contraception throughout the study and for at least 1 week after the final scan
Who may not be able to join:
- People who have previously had a severe allergic reaction to the imaging agent used in this trial (called 18F-fluciclovine)
- People whose cancer has spread to the fluid or lining surrounding the brain and spinal cord
- People who have previously had whole-brain radiation therapy
- People who are unable to have an MRI scan (for example, those with a pacemaker or other safety-related reasons)
- Women who are pregnant at the time the imaging scan is scheduled
- Women who are breastfeeding at the time of the scan and are not willing to pause breastfeeding for 24 hours after the scan is done (a 24-hour pause after the scan is considered acceptable)
- People with serious medical conditions or significant mental health or cognitive difficulties that, in the opinion of the trial doctor, would prevent safe participation or the ability to give informed consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rupesh R Kotecha, MD, Miami Cancer Institute (MCI) at Baptist Health, Inc.
Phone: 17865962000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in sensitivity for PET/CT; Change in sensitivity for MRI; Change in the standardized uptake value (SUV) parameters
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.